Close Menu

lung injury

AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.

The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.

A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.

NEW YORK (GenomeWeb) – Silence Therapeutics this month disclosed that it was ending its work with investigational sepsis drug Atu112 amid disappointing results in preclinical testing.

Silence Therapeutics this week announced that it is closing in on a much-needed financial shot in the arm, inking deals to raise £18.7 million ($28.6 million) through the private placement of 9.5 million shares to certain investors.

Silence Therapeutics this week announced that it has generated preclinical data showing that its acute lung injury drug Atu111 could boost the survival of mice infected with pneumonia when combined with antibiotics.

The company also said that the planned closing of its California facility is expected to be completed in the third quarter.

Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.